A novel gene therapy (ABBV-RGX-314) was well tolerated and reduced treatment burden in patients with bilateral neovascular age-related macular degeneration (AMD), according to results of a phase II ...

Missed injections for weeks or months can trigger vision damage that isn't always fully reversible in patients with neovascular age-related macular degeneration (wet AMD), according to Carl Regillo, ...

Ocugen OCGN is advancing a retinal pipeline built around durability and breadth. Its focus is a modifier gene therapy platform aimed at inherited retinal diseases and blindness conditions, using ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . At Clinical Trials at the Summit, Abbey addressed concerns about using gene therapy in both eyes. However, in 11 ...